As FK228 (depsipeptide) is an FDA approved class I HDAC inhibitor used to treat cutaneous T-cell lymphoma [33], studies combining HDAC inhibitors with standard of care treatments for PDAC are warranted and may result in enhanced tumor penetration with reduced toxicity compared to other therapeutic modalities. The gene discussed is HDAC9; the disease is neoplasm.